Pressure
BioSciences’ (OTCQB: PBIO) patented pressure cycling technology
(“PCT”) platform was recently described as an integral part of women’s cancer
research efforts during a presentation at the International Gynecologic Cancer
Society conference in Brazil. An article discussing the company reads,
“Pressure BioSciences’ PCT platform, as an integral part of the analytical
trio, prepares the excised cells for micro-scale quantitative proteomics and
phosphoproteomics – the large-scale study of proteins and their
phosphorylation-based signaling networks – by provoking rapid and efficient
high-quality cellular protein release and preparation from the biopsy samples.
The entire sample preparation process is done in the company’s proprietary
Barocycler 2320EXT system. . . . The researchers presented an explanation of
their working process in searching for ways to combat gynecological cancers
during a core session of the annual International Gynecologic Cancer Society
(“IGCS”) conference last month in Rio de Janeiro, Brazil. Dr. Larry Maxwell, a
gynecologic oncologist and the OB-GYN chairman at Northern Virginia’s Inova
Fairfax Hospital, described the PCT-based Barocycler system technology provided
by Pressure BioSciences as ‘an essential requirement for our novel workflow in
meeting our goals’ in his presentation to the IGCS.”
To view the full article, visit http://ibn.fm/nKoe9
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired, patented technology from BaroFold,
Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract
services sector, and (2) the use of its recently-patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i)
create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and
water) and to (ii) prepare higher quality, homogenized, extended shelf-life or
room temperature stable low-acid liquid foods that cannot be effectively preserved
using existing non-thermal technologies. For more information, visit the
company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.htm
